PremaAbrahamMD

Ophthalmology • Rapid City, SD

Retinal Disease

Medical Director The Retina Center Black Hills Regional Eye Institute

Join to view full profile

Dr. Abraham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abraham's full profile

Already have an account?

Office
2800 3rd St
Rapid City, SD 57701
Phone+1 605-341-2000

Fax+1 605-719-3211

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Surgical Retina and Vitreous, 1993 - 1995
University of Utah HealthResidency, Ophthalmology, 1990 - 1993
University of Arkansas For Medical Sciences College of MedicineClass of 1989

Certifications & Licensure

SD State Medical License Active through 2025
WY State Medical License 2021 - 2025
PA State Medical License 1993 - 1996
UT State Medical License 1990 - 1996
AR State Medical License 1989 - 1991
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Medflow EHR, Medflow, Inc., 2012-2013

Clinical Trials

Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study Start of enrollment: 2010 Feb 01
Completed
Phase 2
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) Start of enrollment: 2012 Feb 01
Terminated
Phase 2
Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment Start of enrollment: 2012 Nov 01
Completed
Phase 4
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Start of enrollment: 2014 Sep 01
Completed
Phase 3
Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
Completed
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Start of enrollment: 2014 Sep 17
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

21 citations
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Charles C Wykoff, David M Brown, Kimberly Reed, Alyson J Berliner, Adam T Gerstenblith
JAMA Ophthalmology. 2023-09-01
12 citations
Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Clement K Chan, Maziar Lalezary, Prema Abraham, Michael Elman, Wesley Thomas Beaulieu
Ophthalmology. Retina. 2022-06-01
1 citations
Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD.
Daniel Lee, Clement K. Chan, Prema Abraham, David Sarraf
European Journal of Ophthalmology. 2021-05-01

Press Mentions

Christopher A. Durham, MD, Vascular SurgeonJuly 20th, 2021